EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease

Joshua D Grill iD, Charlene Flournoy, Shobha Dhadda, Karin Ernstrom, Reisa Sperling, Doris Molina-Henry, Kate Tranotti, Russell Harris, Michio Kanekiyo, Michelle Gee, Michael Irizarry, Lynn Kramer und 2 weitere

Annals of Neurology · 2024

DOI: 10.1002/ana.26819 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, 2024. Verfasst von Joshua D Grill und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Memory Impairments and Neurological Disorders, Departments of Psychiatry and Human Behavior and Neurobiology and Behavior, University o…. Hauptthemen laut MEDLINE: Alzheimer Disease, Antibodies, Monoclonal, Humanized, Patient Selection. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Many factors contribute to inadequate diversity in Alzheimer disease (AD) clinical trials. We evaluated eligibility rates among racial and ethnic groups at US sites in large global multisite trials in early AD.

Methods

Using screening data from 4 randomized, double‐blind, placebo‐controlled clinical trials in early AD, we assessed rates of eligibility among racial and ethnic groups controlling for other demographic covariates. Each trial incorporated positron emission tomography and/or cerebrospinal fluid to evaluate brain amyloid pathology, as well as typical eligibility criteria used in early AD trials.

Results

Across the trials, 10,804 US participants were screened: 193 (2%) were of Hispanic ethnicity and Black race, 2,624 (25%) were of Hispanic ethnicity and White race, 118 (1%) were of non‐Hispanic ethnicity (NH) and Asian race, 696 (7%) were of NH ethnicity and Black race, and 7,017 (65%) were of NH ethnicity and White race. Data from 156 participants who did not fit into these categories were excluded. Accounting for age, sex, and trial and using NH White participants as a reference group, we observed higher probabilities of ineligibility for amyloid biomarker criteria among Hispanic Black (odds ratio [OR] = 3.20, 95% confidence interval [CI] = 2.11–4.88), Hispanic White (OR = 4.15, 95% CI = 3.58–4.83), NH Asian (OR = 2.35, 95% CI = 1.23–4.55), and NH Black (OR = 3.75, 95% CI = 2.80–5.06) participants.

Interpretation

Differential eligibility may contribute to underrepresentation of some minoritized racial and ethnic groups in early AD trials. Amyloid biomarker eligibility is a requirement to confirm the diagnosis of AD and for treatment with amyloid‐lowering drugs and differed among racial and ethnic groups. ANN NEUROL 2024;95:288–298

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAntibodies, Monoclonal, HumanizedPatient SelectionHumansBiomarkersEthnicityRandomized Controlled Trials as TopicClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicAsianBlack or African AmericanWhiteHispanic or LatinoRacial Groups

Substanzen

Antibodies, Monoclonal, HumanizedBiomarkerslecanemab

Autor:innen und Institutionen

  • Institute for Memory Impairments and Neurological Disorders, Departments of Psychiatry and Human Behavior and Neurobiology and Behavior, University of California, Irvine, Irvine, CA, USA.
  • Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA.
  • Eisai Inc, Nutley, NJ, USA.
  • Brigham and Women's Hospital, Massachusetts General Hospital, Boston, MA, USA.
  • Eisai Co Ltd, Hatfield, UK.

ORCID-Profile: Joshua D Grill

Förderung

  • NIA NIH HHS

Zitieren

APA

Grill, J. D., Flournoy, C., Dhadda, S., Ernstrom, K., Sperling, R., Molina-Henry, D., Tranotti, K., Harris, R., Kanekiyo, M., Gee, M., Irizarry, M., Kramer, L., Aisen, P., & Raman, R. (2024). Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease. Annals of Neurology. https://doi.org/10.1002/ana.26819

Vancouver

Grill JD, Flournoy C, Dhadda S, Ernstrom K, Sperling R, Molina-Henry D, et al. Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease. Annals of Neurology. 2024. doi:10.1002/ana.26819

BibTeX
@article{Grill2024,
  author = {Grill, Joshua D and Flournoy, Charlene and Dhadda, Shobha and Ernstrom, Karin and Sperling, Reisa and Molina-Henry, Doris and Tranotti, Kate and Harris, Russell and Kanekiyo, Michio and Gee, Michelle and Irizarry, Michael and Kramer, Lynn and Aisen, Paul and Raman, Rema},
  title = {Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease},
  journal = {Annals of Neurology},
  year = {2024},
  doi = {10.1002/ana.26819}
}
Kostenlos starten →